Systemic and Target-Site Pharmacokinetics of Antiparasitic Agents
Open Access
- 1 July 2020
- journal article
- review article
- Published by Springer Science and Business Media LLC in Clinical Pharmacokinetics
- Vol. 59 (7), 827-847
- https://doi.org/10.1007/s40262-020-00871-5
Abstract
About one-sixth of the world's population is affected by a neglected tropical disease as defined by the World Health Organization and Center for Disease Control. Parasitic diseases comprise most of the neglected tropical disease list and they are causing enormous amounts of disability, morbidity, mortality, and healthcare costs worldwide. The burden of disease of the top five parasitic diseases has been estimated to amount to a total 23 million disability-adjusted life-years. Despite the massive health and economic impact, most drugs currently used for the treatment of parasitic diseases have been developed decades ago and insufficient novel drugs are being developed. The current review provides a compilation of the systemic and target-site pharmacokinetics of established antiparasitic drugs. Knowledge of the pharmacokinetic profile of drugs allows for the examination and possibly optimization of existing dosing schemes. Many symptoms of parasitic diseases are caused by parasites residing in different host tissues. Penetration of the antiparasitic drug into these tissues, the target site of infection, is a prerequisite for a successful treatment of the disease. Therefore, for the examination and improvement of established dosing regimens, not only the plasma but also the tissue pharmacokinetics of the drug have to be considered. For the current paper, almost 7000 scientific articles were identified and screened from which 429 were reviewed in detail and 100 were included in this paper. Systemic pharmacokinetics are available for most antiparasitic drugs but in many cases, not for all the relevant patient populations and only for single- or multiple-dose administration. Systemic pharmacokinetic data in patients with organ impairment and target-site pharmacokinetic data for relevant tissues and body fluids are mostly lacking. To improve the treatment of patients with parasitic diseases, research in these areas is urgently needed.This publication has 131 references indexed in Scilit:
- The Effect of a High-Fat Breakfast on the Pharmacokinetics of Moxidectin in Healthy Male Subjects: A Randomized Phase I TrialThe American Journal of Tropical Medicine and Hygiene, 2012
- Excretion of Moxidectin into Breast Milk and Pharmacokinetics in Healthy Lactating WomenAntimicrobial Agents and Chemotherapy, 2011
- Pharmacokinetics of combined treatment with praziquantel and albendazole in neurocysticercosisBritish Journal of Clinical Pharmacology, 2011
- Paromomycin for the Treatment of Visceral Leishmaniasis in Sudan: A Randomized, Open-Label, Dose-Finding StudyPLoS Neglected Tropical Diseases, 2010
- Pharmacokinetics of Liposomal Amphotericin B in Pleural FluidAntimicrobial Agents and Chemotherapy, 2010
- Albendazole and its metabolites in the breast milk of lactating women following a single oral dose of albendazoleBritish Journal of Clinical Pharmacology, 2009
- Pulmonary Epithelial Lining Fluid Concentrations after Use of Systemic Amphotericin B Lipid FormulationsAntimicrobial Agents and Chemotherapy, 2009
- Pharmacokinetics and Buccal Mucosal Concentrations of a 15 Milligram per Kilogram of Body Weight Total Dose of Liposomal Amphotericin B Administered as a Single Dose (15 mg/kg), Weekly Dose (7.5 mg/kg), or Daily Dose (1 mg/kg) in Peripheral Stem Cell Transplant PatientsAntimicrobial Agents and Chemotherapy, 2009
- Penetration of Amphotericin B Lipid Formulations into Pleural EffusionAntimicrobial Agents and Chemotherapy, 2007
- Pharmacokinetics of Tinidazole in Male and Female SubjectsThe Journal of Clinical Pharmacology, 1982